Nanorobot Vascular Cleaning System NanoClear Completes First Human Trial: Clearing Artery Plaque Without Surgery

Nanorobot Vascular Cleaning System NanoClear Completes First Human Trial

On March 15, 2029, Germany's Max Planck Institute for Intelligent Systems announced that its NanoClear nanorobot vascular cleaning system completed its first human clinical trial at Munich University Hospital. A 62-year-old patient with coronary atherosclerosis underwent NanoClear treatment in a procedure lasting just 45 minutes, without traditional bypass surgery or stent placement.

NanoClear robots are approximately 200 nanometers in diameter, composed of a magnetic iron oxide core and a biodegradable polymer shell. After intravenous injection, external magnetic fields guide the robots along blood vessels to the target location. The robot's shell carries a specific enzyme that identifies and breaks down oxidized low-density lipoprotein in arterial plaque.

Max Planck Institute team lead Professor Peer Fischer said: "Traditional cardiovascular surgery requires cutting open blood vessels or implanting foreign objects. NanoClear's philosophy is to achieve maximum therapeutic effect with minimum intervention — the robot enters the body to do its work, then degrades and is expelled on its own."

The first patient was able to get out of bed within 24 hours post-surgery. A one-week post-operative imaging examination showed coronary artery stenosis had decreased from 72% pre-surgery to 45%. No significant adverse reactions have been observed so far.

However, Charité Hospital Berlin cardiovascular surgery director Volkmar Falk cautioned: "A single success is encouraging, but there's a long road from 1 case to 1,000 cases. The nanorobots' navigation accuracy, controllability in complex blood flow environments, and long-term biosafety all need validation through larger-scale trials."